Skip to main
ANIP

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals is expecting a meaningful increase in quarterly revenue in the second half of 2026 driven by the 50% expansion in their sales force, and their overall earnings and non-GAAP EPS were ahead of expectations in 2Q 2026. Despite moderating guidance for their Rare Disease segment, we remain bullish on the company's long-term prospects given the potential for Cortrophin sales to exceed $800M annually by 2029 and a strong generics business.

Bears say

ANI Pharmaceuticals is currently facing several fundamental challenges that may negatively impact their financial performance in the long term. These challenges include the potential for unforeseen clinical, regulatory, manufacturing, or commercial setbacks or delays, especially with their Purified Cortrophin Gel and ILUVIEN products, as well as continued challenges with the Alimera integration and executing attractive deals in the future. Additionally, the company may also face worsening pricing and competitive pressures in the generics industry.

ANI Pharma (ANIP) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 5 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.